NCT00457275已完成3 期
A Multicentre, Open-Label, Observational Local Study to Evaluate the LDL-C Lowering Effect of Ezetimibe as Prescribed in Daily Routine Practice in the South African Population
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 440
- 主要终点
- Approval
研究概览
简要总结
To evaluate the LDL-C lowering in south african patients with primary hypercholesterolaemia after the addition of ezetimibe 10mg /day to ongoing therapy with a statin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Men or women >18 and <80 years of age
- •Patients receiving statin therapy for a minimum period of 6 weeks prior to visit 1
- •Female patients receiving hormone therapy (including hormone replacement therapy, any estrogen antagonist/agonist, or oral contraceptives) if maintained on a stable dose and regimen for at least 8 weeks prior to visit 1 and if willing to continue the same regimen throughout the study
- •Liver enzyme levels less than or equal to 1.5 times the upper limit of normal with no active liver disease and CPK less than or equal to 1.5 times upper limit of normal at visit 1
排除标准
- •Cardiovascular medications, such as beta-blockers, calcium-channel blockers,
- •angiotensin ii receptor antagonists or anticoagulants (i.e., warfarin) unless
- •treated with a stable regimen for at least 6 weeks prior to randomization and
- •patient agrees to remain on constant regimen for the duration of the study
- •Patients on amiodarone hydrochloride will also be excluded
- •General weight less than 50% of ideal body weight according to the 1983 metropolitan height and weight tables or weighing less than 100 lbs (45 kg)
- •Hypersensitivity to HMG-COA reductase inhibitors
- •Patient has congestive heart failure defined by nyha class III or IV, uncontrolled cardiac arrhythmias, unstable angina pectoris, or myocardial infarction; coronary artery bypass surgery, or angioplasty within 3 months of visit 1
- •Taking lipid-lowering agents including fish oils, cholestin, bile-acid sequestrants
- •and niacin (grater than 200 mg/day) taken within 6 weeks and fibrates taken within 8 weeks prior to visit 1
- •Taking medications that are potent inhibitors of cyp3a4, including cyclosporine,
- •systemic itraconazole or ketoconazole, erythromycin or clarithromycin,
- •nefazodone, verapamil and protease inhibitors
- •Consumption of greater than 250 ml of grapefruit juice/day
- •Taking oral corticosteroids unless used as replacement therapy for pituitary/adrenal disease and on a stable regimen for at least 6 weeks prior to visit 1
- •Treatment with psyllium, other fiber-based laxatives, and/or OTC therapies
- •known to affect serum lipid levels, phytosterol margarines, unless treated with
- •a stable regimen for at least 6 weeks prior to visit 1 and patient agrees to remain on constant regimen for the duration of the study
- •Women who are pregnant or lactating
结局指标
主要结局
Approval
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Centralized Pan-South African Survey on the Undertreatment of HypercholesterolaemiaUndertreatment of HypercholesterolaemiaNCT01027624AstraZeneca3,000
已完成
3 期
Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)HypercholesterolemiaNCT02476006Sanofi998
已完成
3 期
A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)HypercholesterolemiaNCT00783263Organon and Co440
已完成
2 期
Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-CCholesterolemiaDiabetesDiabetes Mellitus, Type 2NCT03531905Esperion Therapeutics, Inc.242
已完成
3 期
Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary SyndromeAcute Coronary SyndromeNCT04873934Novartis Pharmaceuticals400